PAREXEL INTERNATIONAL STATEMENT REGARDING PHASE I REPORT BY U.K. EXPERT SCIENTIFIC GROUP

PAREXEL Consulting, a leading global life sciences consultancy and division of PAREXEL International Corporation (NASDAQ: PRXL), today announced that it has further expanded its risk management and strategic compliance expertise with the appointment of Raymond T. Oji to the position of senior consultant.

PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services organization, today announced that Dr. James J. Vornov, an internationally recognized neuroscience and drug development expert, has joined the Company’s Clinical Research Services group as a Senior Medical Director. Dr.

PAREXEL International Corporation (NASDAQ: PRXL) today announced its financial results for the first quarter ended September 30, 2006.

PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services organization, today announced the formation of a strategic alliance with e-tractions to enhance the Internet marketing services provided through its Medical Communication Services business unit.

PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services organization, today announced that Christopher J. Lindop has been elected to its Board of Directors and will serve on the Board’s Audit Committee.

PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services organization, today announced that musculoskeletal expert Dr. Sarah Warner has joined the Perceptive Informatics Medical Imaging Services Group as Associate Medical Director.

- Acquisition Adds West Coast Phase I Unit and Specialty Phase II – IV Clinical Research Services -

PAREXEL International Corporation (Nasdaq: PRXL) will release First Quarter Fiscal Year 2007 financial results on Wednesday, October 25, 2006 after the close of the stock market.

PAREXEL International Corporation (Nasdaq: PRXL) announced today it will be presenting at the UBS Global Life Sciences Conference at The Grand Hyatt in New York City.

PAREXEL International Corporation (Nasdaq: PRXL) announced today that Josef von Rickenbach, Chairman and Chief Executive Officer, will be making a formal presentation on PAREXEL at the Bear Stearns 19th Annual Healthcare Conference at the Grand Hyatt in New York City on Monday, September 11th at 10:00 am ET.

PAREXEL Consulting, a leading global life sciences consultancy and division of PAREXEL International Corporation (NASDAQ: PRXL), today announced that it has expanded its risk management and strategic compliance expertise with the appointment of Anthony C. Warchut, formerly an investigator in the U.S. Food and Drug Administration (FDA) Pharmaceutical Inspectorate.

PAREXEL International Corporation (Nasdaq: PRXL) announced today that Josef von Rickenbach, Chairman and Chief Executive Officer, will be presenting at the Thomas Weisel Partners Healthcare Conference at The Four Seasons Hotel in Boston on Wednesday, September 6th at 9:10 am ET.

- Fourth quarter service revenue grows 18% year-over-year, backlog reaches a record $1.1 billion -

PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services provider, today announced that Ellen Zane has been elected to its Board of Directors.

PAREXEL International Corporation (Nasdaq: PRXL) will release Fourth Quarter and Fiscal Year 2006 financial results on Monday, August 7, 2006 after the close of the stock market.

PAREXEL International Corporation (Nasdaq: PRXL) today reported its forward-looking financial expectations for the fourth quarter of Fiscal 2006 (ending June 30, 2006), Fiscal 2006 in its entirety, and Fiscal 2007.

PAREXEL International Corporation (Nasdaq: PRXL) announced today that Josef von Rickenbach, Chairman and Chief Executive Officer, will be making a formal presentation on PAREXEL at the Jefferies Life Sciences Conference at the Mandarin Oriental Hotel in New York City on Wednesday, June 28th at 1:45 pm ET.

PAREXEL International Corporation (Nasdaq: PRXL) will issue earnings guidance for Fiscal 2007 and other periods on Wednesday, July 5, 2006 after the close of the stock market.

-PAREXEL deepens strategic collaboration with clinical research organization Synchron

Several experts from PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services organization, will chair sessions and give presentations during the 42nd Annual Drug Information Association (DIA) Meeting, to be held June 18 – 22, 2006 at the Pennsylvania Convention Center in Philadelphia.

PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services organization, today announced that Douglas A. Batt has been appointed to the role of Senior Vice President and General Counsel.

PAREXEL INTERNATIONAL STATEMENT REGARDING TEGENERO AG PHASE I TRIAL AT NORTHWICK PARK HOSPITAL, U.K.

PAREXEL International Corporation (Nasdaq: PRXL) today announced that it has opened an office in Mexico City to provide clinical research and consulting services.

- Net new business increased by 60.6% from March 2005 quarter - - Backlog up 27.1% versus last year to a record $949 million - - Service revenue up 16.6% year-over-year -

PAREXEL International Corporation (Nasdaq: PRXL) will release Third Quarter Fiscal Year 2006 financial results on Wednesday, April 26, 2006 after the close of the stock market.

PAREXEL International Corporation (Nasdaq: PRXL) announced today that Josef von Rickenbach, Chairman and Chief Executive Officer, will be making a formal presentation on PAREXEL at two upcoming conferences.

PAREXEL International Corporation (Nasdaq: PRXL) announced today it will be presenting at the UBS Global Healthcare Services Conference at The Grand Hyatt in New York City. Josef von Rickenbach, Chairman and Chief Executive Officer, will be making a formal presentation on PAREXEL at 4:30 p.m. ET on Tuesday, February 14th.

- Achieves record quarterly service revenue and backlog -

PAREXEL International Corporation (Nasdaq: PRXL) announced today it will be presenting at the JPMorgan 24th Annual Healthcare Conference at The Westin St. Francis in San Francisco.